Integra Therapeutics — Seed · €10.7M

Integra Therapeutics, a Pompeu Fabra University spin-off developing the FiCAT gene-writing platform, closed a €10.7 million pre-Series A round with no stated lead. New investors EIC Fund (€4M) and CDTI Innvierte (€2.7M) joined existing backers AdBio Partners, Columbus Venture Partners, Invivo Partners and Takeda Ventures to fund preclinical validation of next-generation CAR-T therapies.